← Leaderboards
Daniela E Matei
Jesse Brown Va Medical Center
$9,708,122
Attributed
$15,777,087
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,560,089 · 14
VA$0 · 2
By mechanism
U54$9,021,525 · 3
R01$5,867,605 · 3
UG1$5,460,843 · 1
R21$1,419,874 · 3
P20$704,201 · 1
P30$84,186 · 1
Top collaborators
- Al B Benson11 shared
- Ji-Xin Cheng7 shared
- Kenneth P Nephew5 shared
- Hao F Zhang5 shared
- Vadim Backman4 shared
- David D Nolte4 shared
- John Turek4 shared
- Thomas D. Hurley2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsResistanceChemotherapyTumorMalignant Neoplasm Of OvaryBaseCellsPlatinumResponseCancer CellResourcesCancer Stem CellRecurrenceInnovationPathway InteractionsTechnologyOvarianImageXenograft ProcedureRelapseCancer ModelReportingOvarian NeoplasmStem Cells
Grant awards (64)
Northwestern University Center for Chromatin NanoImaging in Cancer (NU-CCNIC)$1,656,575
U54 · FY2025 · CA
Research Test-Bed Unit$572,616
U54 · FY2025 · CA · contact PI
Northwestern University Lead Academic Participating Site$463,643
UG1 · FY2025 · CA
Translational Research in Malignancies$84,186
P30 · FY2025 · CA · contact PI
Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer$0
I01 · FY2025 · VA · contact PI
Northwestern University Center for Chromatin NanoImaging in Cancer (NU-CCNIC)$1,573,684
U54 · FY2024 · CA
Northwestern University Lead Academic Participating Site$949,402
UG1 · FY2024 · CA
Research Test-Bed Unit$529,581
U54 · FY2024 · CA · contact PI
Northwestern University Lead Academic Participating Site - Revision -5S2$42,000
UG1 · FY2024 · CA
New Epigenetic Targets in Ovarian Cancer Stem Cells$0
I01 · FY2024 · VA · contact PI
Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer$0
I01 · FY2024 · VA · contact PI
Northwestern University Center for Chromatin NanoImaging in Cancer (NU-CCNIC)$1,663,001
U54 · FY2023 · CA
Northwestern University Lead Academic Participating Site$775,160
UG1 · FY2023 · CA
Research Test-Bed Unit$559,123
U54 · FY2023 · CA · contact PI
Northwestern University Lead Academic Participating Site, GY4 Supplemental Request$299,998
UG1 · FY2023 · CA
Center for Chromatin NanoImaging in Cancer$169,298
U54 · FY2023 · CA
New Epigenetic Targets in Ovarian Cancer Stem Cells$0
I01 · FY2023 · VA · contact PI
Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer$0
I01 · FY2023 · VA · contact PI
Northwestern University Center for Chromatin NanoImaging in Cancer (NU-CCNIC)$1,720,444
U54 · FY2022 · CA
Research Test-Bed Unit$577,203
U54 · FY2022 · CA · contact PI
Northwestern University Lead Academic Participating Site$515,160
UG1 · FY2022 · CA
Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells$507,981
R01 · FY2022 · CA · contact PI
Project 02: Tumor Methylomics Analysis Link with Racial Disparities in Ovarian Cancer$257,958
P20 · FY2022 · CA · contact PI
New Epigenetic Targets in Ovarian Cancer Stem Cells$0
I01 · FY2022 · VA · contact PI
Northwestern University Lead Academic Participating Site$895,160
UG1 · FY2021 · CA
Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells$533,761
R01 · FY2021 · CA · contact PI
Northwestern University Lead Academic Participating Site Supplement Year 2$315,000
UG1 · FY2021 · CA
Project 02: Tumor Methylomics Analysis Link with Racial Disparities in Ovarian Cancer$224,525
P20 · FY2021 · CA · contact PI
Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells$116,405
R01 · FY2021 · CA · contact PI
New Epigenetic Targets in Ovarian Cancer Stem Cells$0
I01 · FY2021 · VA · contact PI
Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells$547,720
R01 · FY2020 · CA · contact PI
Northwestern University Lead Academic Participating Site$515,160
UG1 · FY2020 · CA
Project 02: Tumor Methylomics Analysis Link with Racial Disparities in Ovarian Cancer$221,718
P20 · FY2020 · CA · contact PI
Northwestern University Lead Academic Participating Site$175,000
UG1 · FY2020 · CA
Lipid Unsaturation in Ovarian Cancer Stem Cells$115,070
R01 · FY2020 · CA · contact PI
New Epigenetic Targets in Ovarian Cancer Stem Cells$0
I01 · FY2020 · VA · contact PI
Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells$551,416
R01 · FY2019 · CA · contact PI
Northwestern University Lead Academic Participating Site$515,160
UG1 · FY2019 · CA
Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells$567,557
R01 · FY2018 · CA · contact PI
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,695
R01 · FY2018 · CA · contact PI
The Tissue Transglutaminase-Fibronectin Interaction in Ovarian Cancer Metastasis$0
I01 · FY2018 · VA · contact PI
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,044
R01 · FY2017 · CA · contact PI
The Tissue Transglutaminase-Fibronectin Interaction in Ovarian Cancer Metastasis$0
I01 · FY2017 · VA · contact PI
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer$330,976
R01 · FY2016 · EB
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,701
R01 · FY2016 · CA · contact PI
Targeting Ovarian Cancer Stem Cells Through Selective Inhibition of ALDH1A1$169,467
R21 · FY2016 · CA
The Tissue Transglutaminase-Fibronectin Interaction in Ovarian Cancer Metastasis$0
I01 · FY2016 · VA · contact PI
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,700
R01 · FY2015 · CA · contact PI
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer$317,506
R01 · FY2015 · EB
Targeting Ovarian Cancer Stem Cells Through Selective Inhibition of ALDH1A1$203,397
R21 · FY2015 · CA
The Tissue Transglutaminase-Fibronectin Interaction in Ovarian Cancer Metastasis$0
I01 · FY2015 · VA · contact PI
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer$323,700
R01 · FY2014 · CA · contact PI
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer$321,812
R01 · FY2014 · EB
Role of Tissue Transglutaminase in Ovarian Cancer$0
I01 · FY2014 · VA · contact PI
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer$339,561
R01 · FY2013 · EB
Role of Tissue Transglutaminase in Ovarian Cancer$0
I01 · FY2013 · VA · contact PI
Transglutaminase Modulated Tumor-Stroma Interaction in Pancreatic Cancer$203,580
R21 · FY2012 · CA · contact PI
Role of Tissue Transglutaminase in Ovarian Cancer$0
I01 · FY2012 · VA · contact PI
Transglutaminase Modulated Tumor-Stroma Interaction in Pancreatic Cancer$160,789
R21 · FY2011 · CA · contact PI
Role of Tissue Transglutaminase in Ovarian Cancer$0
I01 · FY2011 · VA · contact PI
A Low-Dose Decitabine Strategy for Restoring Ovarian Cancer Sensitivity$341,244
R21 · FY2009 · CA · contact PI
A Low-Dose Decitabine Strategy for Restoring Ovarian Cancer Sensitivity$341,397
R21 · FY2008 · CA · contact PI
A PHASE I TRIAL OF LAPATINIB IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH PL$145
M01 · FY2008 · RR · contact PI
A PHASE I TRIAL OF LAPATINIB IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH PL$1,710
M01 · FY2007 · RR · contact PI